Related by context. All words. (Click for frequent words.) 61 castration resistant prostate cancer 59 hormone refractory prostate cancer 59 castrate resistant prostate cancer 57 NSCLC 56 HRPC 56 prostate cancer CRPC 55 metastatic colorectal cancer 55 HER2 positive metastatic breast 55 pancreatic adenocarcinoma 54 androgen independent 54 prostate cancer AIPC 54 mRCC 54 metastatic renal cell carcinoma 53 metastatic breast cancer 53 metastatic castration resistant 53 recurrent NSCLC 53 metastatic CRPC 53 platinum refractory 53 metastatic melanoma 53 refractory prostate cancer 53 glufosfamide 52 depsipeptide 52 trastuzumab 52 metastatic CRC 52 assessing T DM1 52 dasatinib Sprycel ® 52 heavily pretreated 52 leukemia AML 51 fluoropyrimidine 51 refractory AML 51 vinorelbine 51 mCRC 51 leukemia CLL 51 cell lymphoma CTCL 51 docetaxel 51 relapsed refractory multiple myeloma 51 metastatic hormone refractory 51 ovarian carcinoma 51 relapsed refractory 51 hematologic malignancies 51 refractory multiple myeloma 51 resistant ovarian cancer 51 registrational 51 Bezielle 51 CLL 51 gemcitabine 51 metastatic castrate resistant 50 metastatic malignant melanoma 50 T#I mutation 50 CD# antibody [001] 50 Cloretazine ® 50 bortezomib 50 Cutaneous T 50 metastatic GIST 50 multiple myeloma MM 50 heavily pretreated patients 50 sapacitabine 50 advanced NSCLC 50 lupus nephritis 50 lymphoid malignancies 50 T#I [002] 50 hormone refractory 50 colon carcinoma 50 stage IIIB 50 tumors GIST 50 SWOG 50 paclitaxel carboplatin 50 unresectable 50 nab paclitaxel 50 axitinib 50 mCRC patients 50 gemcitabine Gemzar ® 50 cutaneous T cell 50 huN# DM1 50 CLL SLL 49 gemcitabine carboplatin 49 imatinib resistant 49 hematological cancers 49 neoadjuvant 49 Cloretazine 49 metastatic renal cell 49 ON #.Na 49 tyrosine kinase inhibitors 49 myeloproliferative diseases 49 belinostat 49 recurrent glioblastoma multiforme 49 HGS ETR1 49 EGFR HER2 49 Phase #b/#a clinical 49 chemoradiotherapy 49 cytoreductive nephrectomy 49 neoadjuvant chemotherapy 49 tanespimycin 49 AQ4N 49 gefitinib Iressa 49 histone deacetylase HDAC inhibitor 49 Ozarelix 49 IMGN# 49 HER2 positive breast cancer 49 cutaneous T 49 ENMD 49 metastatic RCC 49 ganetespib 49 cytotoxic chemotherapy 49 paclitaxel poliglumex 49 dasatinib 49 relapsed multiple myeloma 49 metastatic sarcoma 49 HGS ETR2 49 cetuximab Erbitux ® 49 decitabine 49 alvespimycin 49 PXD# 49 erlotinib 49 docetaxel chemotherapy 49 tesmilifene 49 entinostat 49 Phase Ib II 49 OncoVEX GM CSF 49 cetuximab Erbitux R 49 prostate carcinoma 49 hepatoma 49 multiple myeloma 48 gastrointestinal stromal tumor GIST 48 antitumor activity 48 ATL# [001] 48 relapsed AML 48 IRX 2 48 carboplatin paclitaxel 48 untreated multiple myeloma 48 monotherapy 48 relapsing multiple sclerosis 48 luteinizing hormone releasing 48 Advanced Renal Cell 48 IV NSCLC 48 Exelixis XL# 48 MAGE A3 ASCI 48 hepatocellular cancer 48 xenograft models 48 XL# [003] 48 trastuzumab Herceptin ® 48 dasatinib Sprycel 48 targeting CD# 48 adjuvant therapy 48 IMC #B 48 Multiple Myeloma MM 48 medically inoperable 48 Trastuzumab 48 B CLL 48 solid tumors 48 phase IIb clinical 48 INGN 48 obatoclax 48 chronic myeloid leukemia CML 48 refractory colorectal cancer 48 Diffuse Large B 48 recurrent metastatic 48 prostate cancer CaP 48 ADXS# 48 lymphoma CTCL 48 nonmyeloablative 48 IIIA NSCLC 48 HER2 + 48 palifosfamide 48 phase Ib 48 IV metastatic melanoma 48 elacytarabine 48 FOLOTYN 48 ZYBRESTAT TM 48 gastrointestinal stromal tumors 48 ofatumumab 48 histologically confirmed 48 refractory acute myeloid 48 goserelin 48 AP# [003] 48 prostate cancer HRPC 48 BMN 48 estramustine 48 antibody MAb 48 metastatic gastric 48 mitomycin 48 pan HDAC inhibitor 48 unresectable stage 48 BCIRG 48 BiovaxID 48 bevacizumab Avastin ® 47 metastatic prostate cancer 47 INCB# [001] 47 glioblastoma 47 EGFR expressing 47 imatinib Gleevec 47 romidepsin 47 DLBCL 47 Acute Myelogenous Leukemia AML 47 peritoneal carcinomatosis 47 prostate cancer mCRPC 47 Ceflatonin 47 PI3K Akt 47 bendamustine 47 bone metastasis 47 PSMA ADC 47 MGCD# [001] 47 plus prednisone 47 metastatic 47 lymphocytosis 47 PROVENGE 47 enzastaurin 47 refractory NSCLC 47 HER2 negative 47 HER2 positive 47 IgG1 monoclonal antibody 47 sipuleucel T 47 KRAS mutant 47 pancreatic carcinoma 47 pancreatic islet cell 47 biliary tract cancer 47 metastatic HRPC 47 localized renal 47 essential thrombocythemia ET 47 MDA MB 47 gemcitabine cisplatin 47 chronic lymphocytic leukemia CLL 47 chemotherapy regimens 47 unresectable Stage III 47 hematological malignancies 47 Vidofludimus 47 chemotherapeutic agent 47 metastatic malignant 47 Virulizin ® 47 abiraterone acetate 47 T DM1 47 TELCYTA 47 mCRPC 47 ALN TTR 47 imatinib mesylate 47 lenalidomide Revlimid R 47 castration resistant 47 follicular non 47 CanAg 47 adjuvant chemotherapy 47 sunitinib 47 HCV 47 HDACi 47 myelofibrosis 47 K ras mutations 47 NEUVENGE 47 rituximab 47 CBLC# 47 CRp 47 zalutumumab 47 myeloma 47 acute ischemic stroke 47 picoplatin 47 HspE7 47 COU AA 47 clinically localized prostate 47 imatinib therapy 47 ELACYT 47 Gleevec resistant 47 recurrent glioma 47 refractory Hodgkin lymphoma 47 gastrointestinal stromal tumors GIST 47 satraplatin Phase 47 neoadjuvant treatment 47 diagnosed multiple myeloma 47 pertuzumab 47 refractory CLL 47 Castration Resistant Prostate Cancer 47 EOquin 47 recurrent malignant glioma 47 cytotoxic therapy 47 intratumoral injection 47 chemoresistant 47 previously untreated follicular 47 SCCHN 47 histone deacetylase inhibitor 47 relapsed Hodgkin lymphoma 47 PKC# 46 dose escalation clinical 46 recurrent GBM 46 distant metastases 46 relapsed acute myelogenous 46 Quinamed 46 resectable 46 lintuzumab 46 soft tissue sarcoma 46 lorvotuzumab mertansine 46 p# mitogen activated 46 docetaxel Taxotere ® 46 erlotinib Tarceva ® 46 CA4P 46 Omacetaxine 46 metastatic disease 46 pralatrexate 46 VEGFR2 46 sorafenib 46 Aplidin 46 Acute Myeloid Leukemia AML 46 IV melanoma 46 CHOP chemotherapy 46 KRAS wild 46 HBeAg negative 46 castrate resistant 46 Troxatyl 46 distant metastasis 46 pomalidomide 46 INCB# [002] 46 cetuximab 46 hormone LHRH agonist 46 renal cell carcinoma 46 trabectedin 46 basal cell carcinoma BCC 46 Phase #/#a trial 46 IFN α 46 BRIM2 46 cervical carcinoma 46 galiximab 46 Valortim R 46 CEQ# 46 Phase Ib 46 relapsed SCLC 46 imatinib 46 Phase 2a trial 46 elotuzumab 46 operable breast cancer 46 remission induction 46 CR# vcMMAE 46 antiangiogenic therapy 46 ISF# 46 capecitabine 46 tyrosine kinase inhibitor TKI 46 Chronic Lymphocytic Leukemia CLL 46 iniparib BSI 46 pegylated liposomal doxorubicin 46 perifosine 46 talabostat 46 NCCTG 46 TACE 46 non squamous NSCLC 46 eculizumab 46 advanced epithelial ovarian 46 registrational trial 46 adecatumumab 46 haematological malignancies 46 AML 46 Doxil ® 46 HuMax CD4 46 refractory metastatic colorectal cancer 46 ixabepilone 46 recurrent ovarian 46 colorectal carcinoma 46 pT3 46 Tarceva TM 46 thymoma 46 mTOR inhibitor 46 relapsed ovarian cancer 46 constitutively active 46 GW# [003] 46 BEXXAR 46 HGS# 46 Symadex 46 Phase Ib clinical 46 recurrent glioblastoma 46 evaluable 46 receptor tyrosine kinase inhibitor 46 chemoradiation 46 cell lung cancer 46 relapsed MM 46 voreloxin 46 PRTX 46 potent inhibition 46 LUX Lung 46 IV malignant melanoma 46 recurrent ovarian cancer 46 FLT3 46 hepatocellular carcinoma HCC 46 sarcomatoid 46 plus gemcitabine 46 Cotara 46 EGFr 46 Ph + ALL 46 AA amyloidosis 46 dexpramipexole 46 Triapine 46 mapatumumab 46 bone metastases 46 Introgen ADVEXIN 46 epithelial ovarian cancer 46 PegIFN 45 Interferon alfa 45 differentiated thyroid 45 TORISEL 45 Herceptin trastuzumab 45 locoregional 45 hTERT 45 BrachySil TM 45 YONDELIS 45 Glioblastoma Multiforme 45 Telintra 45 Targretin 45 cilengitide 45 Kahalalide F 45 tesetaxel 45 CYT# 45 orthotopic 45 metastatic colorectal 45 BR.# 45 azacitidine 45 fludarabine cyclophosphamide 45 pheochromocytoma 45 hematologic disorders 45 daunorubicin 45 Idiopathic Pulmonary Fibrosis 45 vinca alkaloid 45 anti leukemic 45 adjuvant radiation 45 trastuzumab Herceptin R 45 VELCADE 45 IgG1 antibody 45 randomized Phase 2b 45 follicular NHL 45 invasive bladder 45 imatinib Gleevec ® 45 premalignant 45 farletuzumab 45 evaluating T DM1 45 lumiliximab 45 adverse cytogenetics 45 standard chemotherapy regimens 45 velafermin 45 ALK inhibitor 45 achieve sustained virologic 45 trastuzumab Herceptin 45 nonmetastatic 45 sorafenib Nexavar ® 45 LHRH receptor positive 45 EBRT 45 follicular lymphoma FL 45 AVASTIN 45 RG# [001] 45 temsirolimus 45 mitoxantrone 45 histologies 45 IMA# 45 imetelstat 45 small lymphocytic lymphoma 45 PCa 45 IMC A# 45 EpCAM 45 pegylated liposomal doxorubicin PLD 45 colorectal liver metastases 45 chlorambucil 45 tyrosine kinase inhibitor 45 PEGylated interferon beta 1a 45 hepatocellular carcinoma 45 PROSTVAC ® 45 Phase 2b trial 45 EGFR mutations 45 stage IIIb 45 NY ESO 45 acute promyelocytic leukemia APL 45 acute myeloid leukemia AML 45 curative resection 45 relapsed GBM 45 Vicinium TM 45 HBeAg positive 45 HGPIN 45 phenoxodiol 45 Cloretazine R 45 panobinostat 45 refractory chronic lymphocytic 45 Sezary syndrome 45 rhIL 7 45 BIBW 45 Aplidin R 45 MEND CABG II 45 disease progression 45 hormonal therapy 45 mediated apoptosis 45 malignancies 45 aHUS 45 EGFR tyrosine kinase inhibitors 45 Xanafide 45 ASCT 45 Dacogen injection 45 Neoadjuvant 45 situ CIS 45 LNCaP 45 epirubicin 45 FOLFOX6 45 prospectively defined 45 temozolomide TMZ 45 epithelial tumors 45 superficial bladder cancer 45 Ceflatonin R 45 CoFactor 45 refractory PTCL 45 ErbB2 positive 45 Phase 2b study 45 mg/m2 dose 45 metastatic cancer 45 neoplasia 45 radiation sensitizer 45 dacarbazine 45 advanced pancreatic neuroendocrine 45 KRAS mutant tumors 45 androgen deprivation 45 pDCs 45 oral ridaforolimus 45 microRNA miR 45 breast carcinoma 45 anthracycline taxane 45 neoadjuvant therapy 45 familial amyloidotic polyneuropathy FAP 45 APTIVUS r 45 unresectable liver cancer 45 medullary thyroid cancer 44 Amrubicin 44 secondary hyperparathyroidism 44 TG# [001] 44 CERE 44 cancer mCRC 44 ZACTIMA 44 induces apoptosis 44 pDC 44 talactoferrin 44 endometrial adenocarcinoma 44 low dose cytarabine 44 anthracyclines 44 trastuzumab DM1 T DM1 44 tumor xenograft models 44 idarubicin 44 leukemia ALL 44 Insegia 44 Natalizumab 44 papillary RCC 44 urothelial bladder cancer 44 epithelial ovarian 44 myeloproliferative disorders 44 nilotinib 44 Proxinium TM 44 Bortezomib 44 cisplatin chemotherapy 44 Pharmacokinetics PK 44 MDV# 44 RTOG 44 tyrosine kinase inhibitors TKIs 44 mTOR inhibitors 44 evaluable patients 44 cystectomy 44 E#F# 44 doxorubicin HCl liposome injection 44 blinatumomab 44 CTLs 44 completely resected 44 severe oral mucositis 44 Taxotere ® 44 Imprime PGG 44 5 Fluorouracil 44 haematological cancers 44 SSc 44 squamous 44 Hodgkin lymphoma NHL 44 Torisel 44 OMAPRO 44 Amigal 44 Vectibix monotherapy 44 idiopathic pulmonary fibrosis IPF 44 relapsed follicular 44 Hsp# inhibition 44 proteasome inhibitor 44 underwent resection 44 GVAX Pancreas Vaccine 44 de novo AML 44 relapsing remitting multiple sclerosis 44 HoFH 44 stage IIIb IV 44 FOLFOX 44 ponatinib 44 Pralatrexate 44 Uricase PEG 44 TKIs 44 cisplatin resistant 44 TREANDA 44 viral kinetics 44 chemotherapy docetaxel 44 EGF receptor 44 MGd 44 MDS AML 44 NSABP 44 acute GvHD 44 visilizumab 44 NTx 44 5 fluorouracil 44 cabozantinib 44 androgen receptor AR 44 melphalan prednisone 44 Myelofibrosis 44 Velcade bortezomib 44 XmAb# 44 K RAS 44 Taxotere R 44 GVAX 44 interferon IFN 44 Marqibo 44 CALGB # [001] 44 3 registrational trial 44 Genasense 44 thymalfasin 44 milatuzumab 44 FOLFIRI 44 myelofibrosis polycythemia vera 44 complete remissions 44 anti angiogenic therapy 44 sunitinib malate 44 hepatic metastases 44 forodesine 44 rindopepimut 44 Tarceva erlotinib 44 valopicitabine 44 ocrelizumab 44 PFS 44 liver metastases 44 metastatic breast 44 Neuradiab 44 metastatic androgen independent 44 amrubicin 44 Alocrest 44 oblimersen 44 CANCIDAS 44 PI3K inhibitor 44 papillary renal cell carcinoma 44 BRCA deficient 44 tocilizumab 44 acute myelogenous leukemia AML 44 vandetanib 44 thalidomide Thalomid 44 MEK inhibitor 44 TroVax 44 malignant pleural mesothelioma 44 GvHD 44 metastatic cancers 44 lymphadenectomy 44 interferon beta 1a 44 chemotherapeutic agents 44 surgically resectable 44 APPRAISE 44 pancreatic neuroendocrine tumors 44 antiretroviral naïve 44 Hodgkin lymphoma HL 44 IRESSA 44 Zybrestat 44 acute myeloid 44 nilotinib Tasigna ® 44 refractory metastatic 44 thyroid carcinoma 44 relapsed CLL 44 Metastatic Breast Cancer 44 taxane 44 null responder HCV 44 metastatic NSCLC 44 paclitaxel Taxol 44 mutational status 44 Rituxan rituximab 44 splenectomized patients 44 BCG refractory 44 Gemcitabine 44 FOLPI 44 bevacizumab Avastin 44 Erlotinib 44 Genasense ® 44 sorafenib Nexavar 43 § #.# [002] 43 essential thrombocythemia 43 Renal Cell Carcinoma RCC 43 randomized Phase III 43 Hematologic 43 Phenoptin 43 eosinophilic asthma 43 ara C 43 evaluating REVLIMID 43 systemic lupus erythematosus SLE 43 alkylating agent 43 Li Fraumeni Syndrome 43 advanced metastatic renal 43 CML CP 43 HCV infected 43 cell lymphomas 43 SUTENT 43 unresectable locally advanced 43 IL# PE#QQR 43 acute coronary syndromes ACS 43 GRN#L 43 paclitaxel 43 Gefitinib 43 renal tumors 43 ipilimumab 43 resminostat 43 CYT# potent vascular disrupting 43 ER CHOP 43 afatinib 43 GSTP1 43 prior chemotherapy regimens 43 vemurafenib 43 survivin 43 adriamycin 43 Annamycin 43 Afatinib 43 Acute Coronary Syndromes ACS 43 interferon alfa 2a 43 AVAX 43 cytarabine 43 symptomatic BPH 43 fluorouracil 43 dose cohort 43 evaluating tivozanib 43 refractory indolent non 43 lymphocytic leukemia 43 achieved CCyR 43 IFN alfa 43 Group RTOG 43 elesclomol 43 microwave hyperthermia 43 mycophenolate mofetil 43 Tie2 43 IIIb 43 RNAi therapeutic targeting 43 localized prostate cancer 43 custirsen 43 NPM1 43 erlotinib Tarceva 43 FOLFOX chemotherapy 43 kinase inhibitor 43 cell malignancies 43 fallopian tube cancers 43 Follicular Lymphoma 43 paclitaxel Taxol R 43 clofarabine 43 HCV RESPOND 2 43 chemokine receptor 43 CD8 + 43 myelodysplastic syndrome MDS 43 lymphoproliferative disorders 43 soft tissue sarcomas 43 seliciclib 43 cabazitaxel 43 cetrorelix 43 Acute Myeloid Leukemia 43 papillary 43 Irinotecan 43 DCVax ® Brain 43 trastuzumab emtansine T DM1 43 Aflibercept 43 neratinib 43 Surgical resection 43 Nuvion 43 plus dexamethasone 43 TRISENOX 43 myeloma cells 43 NM# [003] 43 Fludara 43 Lenalidomide 43 VIDAZA 43 metaglidasen 43 severe neutropenia 43 p# biomarker 43 squamous cell carcinoma SCC 43 adjuvant tamoxifen 43 radiolabeled monoclonal antibody 43 CIMZIA ™ 43 endocrine therapy 43 immunosuppressant 43 5 FU 43 myelodysplastic syndromes MDS 43 activating mutations 43 TroVax ® 43 investigational compound 43 colorectal cancer liver metastases 43 BAY #-# 43 bladder carcinoma 43 plasmacytoid 43 EGFR mutation positive 43 gemcitabine chemotherapy 43 Zevalin consolidation 43 KRAS mutations 43 cisplatin 43 KRAS mutation 43 pegfilgrastim 43 5-FU/LV 43 fallopian tube carcinoma 43 carcinoma 43 haematopoietic 43 BRAF mutation 43 chronic HCV infection 43 BEXXAR Therapeutic Regimen 43 autologous stem cell 43 biologic therapy 43 MLL AF9 43 advanced metastatic prostate 43 interferon therapy 43 Hepatocellular Carcinoma HCC 43 trastuzumab DM1 43 dacarbazine chemotherapy 43 Cytoxan 43 Chronic Lymphocytic Leukemia 43 durable remissions 43 Randomized Phase II 43 liposomal doxorubicin 43 EGFR expressing mCRC 43 tyrosine phosphorylation 43 lapatinib 43 carcinoid tumors 43 Neulasta ® 43 radiochemotherapy 43 refractory CTCL 43 hA# 43 Myelodysplastic Syndromes 43 Myelodysplastic Syndrome MDS 43 β2 43 ABRAXANE 43 Gleevec imatinib mesylate 43 regulated kinase 43 SCH # 43 NOD SCID mice 43 zoledronic acid 43 docetaxel Taxotere R 43 Flt3 43 mediated inhibition 43 Myelodysplastic Syndrome 43 randomized Phase 43 adjuvant radiotherapy 43 KRAS mutations occur 43 metastatic colon cancer 43 DAS# remission 43 HERCEPTIN 43 indolent NHL 43 RECIST Response Evaluation Criteria 43 MET amplification 42 metastatic relapsed 42 nimotuzumab 42 cisplatin vinorelbine 42 hypomethylating agents 42 BRIM3 42 pancreatic NET 42 pulmonary metastases 42 EGFR inhibitors 42 topoisomerase 42 cell lymphoma PTCL 42 GISTs 42 mutated KRAS gene 42 EGFR TKI 42 Cell Lymphoma 42 TACI Ig 42 CaP 42 glioblastoma multiforme GBM 42 panitumumab Vectibix 42 AVONEX ® 42 MAGE A3 42 dose limiting toxicities 42 dose cohorts 42 huC# DM4 42 sunitinib Sutent 42 myelodysplastic syndromes 42 prostate adenocarcinoma 42 Mantle Cell Lymphoma 42 Pemetrexed 42 cholangiocarcinoma 42 Cdc7 42 metastatic kidney 42 situ LCIS 42 OPAXIO 42 advanced hepatocellular carcinoma 42 diabetic nephropathy 42 predictive biomarker 42 alpha folate receptor 42 Folfox 42 CMV disease 42 lenalidomide 42 mitogenic 42 Aptivus ® 42 grade cervical intraepithelial 42 postoperative chemotherapy 42 Alpharadin 42 non metastatic osteosarcoma 42 HepG2 cells 42 selective agonist 42 Glufosfamide 42 cytotoxic 42 Evoltra ® 42 metastatic lung cancer 42 Ophena TM 42 Clofarabine 42 NMIBC 42 Talabostat 42 chemotherapeutic 42 tumoral 42 cutaneous melanoma 42 lung carcinomas 42 Soft Tissue Sarcoma 42 1beta 42 squamous histology 42 non resectable 42 Relapsed Refractory 42 Zolinza 42 ADVEXIN 42 TYKERB 42 metastatic pancreatic cancer 42 cytokine refractory 42 vWF 42 5FU 42 FOLFOX4 42 etoposide 42 external beam radiotherapy 42 tumor subtypes 42 CR nPR 42 idiopathic myelofibrosis 42 colorectal adenocarcinoma 42 docetaxel Taxotere 42 bispecific 42 Epidermal Growth Factor Receptor 42 advanced unresectable 42 stage IIIA 42 dated #.#.# [002] 42 BCR ABL 42 MabCampath 42 NSABP B 42 urothelial carcinoma 42 ACRIN 42 Anticalin ® 42 Prognostic factors 42 TRC# 42 gefitinib 42 MYDICAR ® 42 HER2/neu 42 Ofatumumab 42 bosutinib 42 neuroendocrine tumors 42 VEGF receptor 42 Enzastaurin 42 HNSCC 42 temozolomide 42 downstream effectors 42 metastatic carcinoma 42 murine 42 proteasome inhibitor bortezomib 42 p# p# 42 JAK3 42 Perifosine 42 malignant neoplasms 42 EGFR mutated 42 Acute Myeloid Leukaemia AML 42 tivozanib 42 Taxotere 42 malignant ovarian 42 steroidogenesis 42 dirucotide 42 interferon alfa 42 myeloid 42 Rituxan 42 PegIFN RBV 42 alpha#beta# integrin 42 Epratuzumab 42 angiogenesis inhibition 42 myeloid metaplasia 42 invasive carcinoma 42 systemic lupus erythematosus 42 non squamous 42 Romidepsin 42 TTR amyloidosis 42 TAXOTERE R 42 recurrent malignant gliomas 42 T#I mutant 42 Fludara ® 42 nucleoside analogue 42 autoimmune hemolytic anemia 42 dose cytarabine 42 tamibarotene 42 Evoltra TM 42 N methyl 42 HuMax CD# 42 methylnaltrexone 42 μg liter 42 humanized antibody 42 metachronous 42 transthyretin amyloidosis 42 panitumumab 42 stage IIIB IV 42 AEG# 42 ACTEMRA TM 42 Receptor Antagonists 42 CTGF 42 embryonal carcinoma 42 satraplatin 42 recurrent prostate cancer 42 sarcoma 42 ipsilateral breast 41 CTCE 41 tumor recurrence 41 ASA#